Abstract
A new series of pyrazolo[3,4-d]pyrimidine analogues bearing different amino acid conjugates 10(a-m) were synthesized with the aim to evaluate their antitumor effect through simultaneous inhibition of human dihydrofolate reductase (hDHFR). All novel compounds were tested to screen their enzyme inhibition activity against (hDHFR) beside their in vitro cytotoxicity against six human MTX resistant cancer cell lines namely, human prostate cancer (PC-3), pancreatic human cancer cell lines (BxPC-3), colorectal carcinoma (HCT-116), human hepatocellular carcinoma (HepG-2), cervical carcinoma (HeLa), and mammary gland breast cancer (MCF-7), besides normal immortalized pancreatic cell line (HPDE). Compounds 10(e), 10(f), 10(g) inhibited DHFR at considerable low (IC50 < 1 mu M) in comparison to MTX (IC50 = 5.61 mu M) beside their characteristic cytotoxic effects on different resistant cancer cell lines. Flow cytometry was done for the most active candidate compound 10(e) against MCF-7 breast cancer cell line. The results illustrated that compound 10(e) induced apoptosis and arrested MCF-7 cell cycle in the G1/S phase. Western blot for visualization and quantification was used to confirm the capability of compound 10(e) to induce the expression of proapoptotic caspases and Bax proteins in MCF-7 breast cancer cell line beside its ability to reduce the expression of antiapoptotic Bcl-2 protein. Molecular modeling studies demonstrated that compound 10(e) elucidated binding energy of (S= -8.4390 Kcal/mol) that exceed that of the normal ligand MTX (S= -8.3951Kcal/mol) in addition to several favorable binding interactions with the active site residues.